ONC201 Glioblastoma Trial to Expand Based on Promising Initial Results

NeOnc Technologies receives California Investment Forum’s Breakthrough Medical Technology Achievement Award

NeOnc Technologies Holdings Inc., a clinical-stage biopharmaceutical company, has received the Breakthrough Medical Technology Achievement Award from the California Investment Forum for its innovations in medical technology related to the treatment of brain and central nervous system diseases.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Serotonin-producing neurons regulate malignancy in ependymoma brain tumors

A study published in Nature reveals the functional relevance of tumor-neuron interactions that regulate the growth of ependymoma brain tumors.

August 02, 2024

Vol.50 No.31

Clinical Roundup

AI system identifies genes that can convert brain cancer cells into functioning immune cells in mice

In an innovative new study of glioblastoma, scientists used artificial intelligence to reprogram cancer cells, converting them into dendritic cells, which can identify cancer cells and direct other immune cells to kill them.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Unexpected role of OTX2 drives aggressive medulloblastoma

Researchers at Baylor College of Medicine, Texas Children’s Hospital, the University of Manitoba, and collaborating institutions revealed an unexpected way in which the protein OTX2 drives the progression of medulloblastoma—the most common aggressive childhood brain cancer.

July 19, 2024

Vol.50 No.29

In Brief

Linda Liau elected to Taiwan’s Academia Sinica

Linda Liau, chair of neurosurgery at the David Geffen School of Medicine at UCLA, was elected as an Academician of Academia Sinica by the 35th Convocation of Academicians, the preeminent academic institution in Taiwan.

July 12, 2024

Vol.50 No.28